Published in J Natl Cancer Inst on June 20, 2001
St. Gallen 2011: Summary of the Consensus Discussion. Breast Care (Basel) (2011) 1.62
Prognostic molecular markers in early breast cancer. Breast Cancer Res (2004) 1.56
Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring. Genome Biol (2007) 1.43
Biomarkers in Breast Cancer - An Update. Geburtshilfe Frauenheilkd (2012) 1.41
Molecular circuits of solid tumors: prognostic and predictive tools for bedside use. Nat Rev Clin Oncol (2010) 1.36
Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon? EPMA J (2013) 1.17
Interdisciplinary GoR level III Guidelines for the Diagnosis, Therapy and Follow-up Care of Breast Cancer: Short version - AWMF Registry No.: 032-045OL AWMF-Register-Nummer: 032-045OL - Kurzversion 3.0, Juli 2012. Geburtshilfe Frauenheilkd (2013) 1.14
Prognostic value of PAI1 in invasive breast cancer: evidence that tumor-specific factors are more important than genetic variation in regulating PAI1 expression. Cancer Epidemiol Biomarkers Prev (2006) 1.06
Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6×FEC versus 3×FEC/3×Docetaxel. BMC Cancer (2011) 1.03
The changing role of pathology in breast cancer diagnosis and treatment. Pathobiology (2011) 1.02
uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies. Breast Cancer Res (2014) 1.02
Breast cancer and metabolic syndrome linked through the plasminogen activator inhibitor-1 cycle. Bioessays (2007) 0.92
Elevated expression of polymorphonuclear leukocyte elastase in breast cancer tissue is associated with tamoxifen failure in patients with advanced disease. Br J Cancer (2003) 0.89
Independent prognostic value of angiogenesis and the level of plasminogen activator inhibitor type 1 in breast cancer patients. Br J Cancer (2003) 0.87
Influence of preoperative core biopsies on uPA/PAI-1 expression in breast cancer tissue. Virchows Arch (2008) 0.87
The Oral Serine Protease Inhibitor WX-671 - First Experience in Patients with Advanced Head and Neck Carcinoma. Breast Care (Basel) (2008) 0.87
Targeted therapies in cancer - challenges and chances offered by newly developed techniques for protein analysis in clinical tissues. J Cancer (2010) 0.86
Identification of a three-gene expression signature of poor-prognosis breast carcinoma. Mol Cancer (2004) 0.86
Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive breast cancer. BMC Cancer (2006) 0.84
Non-invasive proteomics-thinking about personalized breast cancer screening and treatment. EPMA J (2010) 0.82
Assessment of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in Breast Cancer Tissue: Historical Aspects and Future Prospects. Breast Care (Basel) (2008) 0.82
[Prognostic and predictive factors of invasive breast cancer: update 2009]. Pathologe (2009) 0.82
Cyr61 and YB-1 are novel interacting partners of uPAR and elevate the malignancy of triple-negative breast cancer. Oncotarget (2016) 0.80
Progesterone receptor isoforms PRA and PRB differentially contribute to breast cancer cell migration through interaction with focal adhesion kinase complexes. Mol Biol Cell (2013) 0.80
Plasminogen activator urokinase expression reveals TRAIL responsiveness and supports fractional survival of cancer cells. Cell Death Dis (2014) 0.80
Inhibition of urokinase-type plasminogen activator expression by dihydroartemisinin in breast cancer cells. Oncol Lett (2014) 0.79
Accumulation of uPA-PAI-1 complexes inside the tumour cells is associated with axillary nodal invasion in progesterone-receptor-positive early breast cancer. Br J Cancer (2003) 0.79
Adjuvant Systemic Therapy of Breast Cancer. Breast Care (Basel) (2011) 0.79
Correlation between metastatic potential and variants from colorectal tumor cell line HT-29. World J Gastroenterol (2003) 0.79
Targeting tumor cell invasion and dissemination in vivo by an aptamer that inhibits urokinase-type plasminogen activator through a novel multifunctional mechanism. Mol Cancer Res (2012) 0.79
Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer - correlation with traditional prognostic factors. Radiol Oncol (2015) 0.78
uPA/PAI-1 ratios distinguish benign prostatic hyperplasia and prostate cancer. J Cancer Res Clin Oncol (2013) 0.78
An ultra-sensitive immunoassay for quantifying biomarkers in breast tumor tissue. J Cancer (2014) 0.78
Experience in Phase I Trials and an Upcoming Phase II Study with uPA Inhibitors in Metastatic Breast Cancer. Breast Care (Basel) (2008) 0.77
Candidate prognostic markers in breast cancer: focus on extracellular proteases and their inhibitors. Breast Cancer (Dove Med Press) (2014) 0.77
The patient experience. Breast Cancer Res Treat (2007) 0.77
Role of urokinase plasminogen activator and plasminogen activator inhibitor mRNA expression as prognostic factors in molecular subtypes of breast cancer. Onco Targets Ther (2014) 0.76
Urokinase expression in course of benign and malignant mammary lesions: comparison between nodular and healthy tissues. J Cancer Res Clin Oncol (2009) 0.76
Prospective Biomarker Trials Chemo N0 and NNBC-3 Europe Validate the Clinical Utility of Invasion Markers uPA and PAI-1 in Node-Negative Breast Cancer. Breast Care (Basel) (2008) 0.76
Biomolecular features of clinical relevance in breast cancer. Eur J Nucl Med Mol Imaging (2004) 0.76
In vivo anti-metastatic effects of uPAR retargeted measles virus in syngeneic and xenograft models of mammary cancer. Breast Cancer Res Treat (2014) 0.76
Prognostic significance of uPA/PAI-1 level, HER2 status, and traditional histologic factors for survival in node-negative breast cancer patients. Radiol Oncol (2016) 0.75
High Expression of Urokinase-Type Plasminogen Activator Is Associated with Lymph Node Metastasis of Invasive Ductal Carcinoma of the Breast. J Breast Cancer (2016) 0.75
uPAR enhances malignant potential of triple-negative breast cancer by directly interacting with uPA and IGF1R. BMC Cancer (2016) 0.75
Node-Negative Breast Cancer: Which Patients Should Be Treated? Breast Care (Basel) (2008) 0.75
uPAR Expression Pattern in Patients with Urothelial Carcinoma of the Bladder--Possible Clinical Implications. PLoS One (2015) 0.75
Chemoendocrine Treatment Is Standard in Hormone Receptor-Positive Patients. Breast Care (Basel) (2008) 0.75
Adjuvant Systemic Therapy, Quo Vadis? Patient Selection, Prognostic and Predictive Factors. Breast Care (Basel) (2008) 0.75
Plasminogen Activator System and Breast Cancer: Potential Role in Therapy Decision Making and Precision Medicine. Biomark Insights (2016) 0.75
Decision impact and feasibility of different ASCO-recommended biomarkers in early breast cancer: Prospective comparison of molecular marker EndoPredict and protein marker uPA/PAI-1. PLoS One (2017) 0.75
Clinical significance of the quantitative assessment of the cytosolic concentration of HER-2/neu protein in breast cancer by immunoenzymatic assay (ELISA). J Cancer Res Clin Oncol (2005) 0.75
Assessment of Ki67 and uPA/PAI-1 expression in intermediate-risk early stage breast cancers. BMC Cancer (2017) 0.75
High risk of squamous cell carcinoma of the cervix for women with HLA-DQw3. Nature (1991) 3.32
Exploring feature-based approaches in PET images for predicting cancer treatment outcomes. Pattern Recognit (2009) 3.32
Triple-negative breast cancer--current status and future directions. Ann Oncol (2009) 2.78
Country profile: Germany. Lancet (1996) 2.77
Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b. Oncogene (2000) 2.71
Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 2.63
Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol (2000) 2.58
Noninvasive detection and evaluation of atherosclerotic coronary plaques with multislice computed tomography. J Am Coll Cardiol (2001) 2.57
The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays. Cancer Immunol Immunother (2007) 2.49
Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT '91. Int J Radiat Oncol Biol Phys (2000) 2.33
Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol (2000) 2.28
Increased neutrophil-platelet adhesion in patients with unstable angina. Circulation (1996) 2.20
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res (2000) 2.09
Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res (2001) 2.06
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol (2007) 2.05
Quality of care of VLBW neonates: relationship between unit volume and outcome is different between metropolitan and rural regions. Acta Paediatr (2008) 2.04
[S3-Guidelines Conference "Colorectal Carcinoma" 2004]. Z Gastroenterol (2004) 2.03
Influence of Nitrate and Ammonia on Photosynthetic Characteristics and Leaf Anatomy of Moricandia arvensis. Plant Physiol (1982) 2.02
Friedreich's ataxia: point mutations and clinical presentation of compound heterozygotes. Ann Neurol (1999) 2.02
Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat (1993) 1.97
1st International consensus guidelines for advanced breast cancer (ABC 1). Breast (2012) 1.96
Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res (1995) 1.83
Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost (1997) 1.78
Evolution of the Friedreich's ataxia trinucleotide repeat expansion: founder effect and premutations. Proc Natl Acad Sci U S A (1997) 1.76
Spatial and temporal regulation of gap junction connexin43 in vascular endothelial cells exposed to controlled disturbed flows in vitro. Proc Natl Acad Sci U S A (1999) 1.75
High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res (2001) 1.70
[Reliable micromethod for determination of the protein content in tissue homogenates]. Acta Biol Med Ger (1975) 1.69
BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood (1994) 1.68
Transverse-momentum and pseudorapidity distributions of charged hadrons in pp collisions at square root of s = 7 TeV. Phys Rev Lett (2010) 1.67
Expression of the peripheral-type benzodiazepine receptor and apoptosis induction in hepatic stellate cells. Gastroenterology (2001) 1.66
Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol (2001) 1.62
EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer. J Clin Pathol (2009) 1.58
Qualitative and quantitative assessment of C3-receptor reactivities on lymphoid and phagocytic cells. J Immunol (1981) 1.57
Study of the mass and spin-parity of the Higgs boson candidate via its decays to Z boson pairs. Phys Rev Lett (2013) 1.56
Tumour-associated proteolytic factors uPA and PAI-1 and survival in totally resected gastric cancer. Lancet (1994) 1.56
High prevalence of testicular adrenal rest tumors, impaired spermatogenesis, and Leydig cell failure in adolescent and adult males with congenital adrenal hyperplasia. J Clin Endocrinol Metab (2001) 1.52
Management of venous port systems in oncology: a review of current evidence. Ann Oncol (2007) 1.52
[Diagnosis and therapy of carpal tunnel syndrome--guideline of the German Societies of Handsurgery, Neurosurgery, Neurology, Orthopaedics, Clinical Neurophysiology and Functional Imaging, Plastic, Reconstructive and Aesthetic Surgery, and Surgery for Traumatology]. Handchir Mikrochir Plast Chir (2007) 1.51
Differential subcellular localization of functionally divergent survivin splice variants. Cell Death Differ (2002) 1.50
Bilateral spastic cerebral palsy--a collaborative study between southwest Germany and western Sweden. III: Aetiology. Dev Med Child Neurol (1995) 1.50
Early detection of aspergillus infection after allogeneic stem cell transplantation by polymerase chain reaction screening. J Infect Dis (2000) 1.47
LPS and TNFalpha induce SOCS3 mRNA and inhibit IL-6-induced activation of STAT3 in macrophages. FEBS Lett (1999) 1.46
Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemost (1991) 1.46
Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res (1992) 1.44
Acute and one year follow-up results after vessel size adapted PTCA using intracoronary ultrasound. Eur Heart J (1998) 1.42
The relevance of circulating epithelial tumor cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer. Ann Oncol (2007) 1.42
Optimized differential diagnosis of breast lesions by combined B-mode and color Doppler sonography. Ultrasound Obstet Gynecol (1997) 1.41
Quality of life measurement in children and adolescents: issues, instruments, and applications. J Clin Psychol (2001) 1.40
Observation of B(0)(s)-->Psi(2S)Phi and measurement of the ratio of branching fractions Beta(B(0)(s)-->Psi(2S)Phi)/Beta(B(0)(s)-->J/PsiPhi). Phys Rev Lett (2006) 1.40
Isolated spastic paraparesis leading to diagnosis of Friedreich's ataxia. J Neurol Neurosurg Psychiatry (2000) 1.40
Efficacy of bath psoralen plus ultraviolet A (PUVA) vs. system PUVA in psoriasis: a prospective, open, randomized, multicentre study. Br J Dermatol (2013) 1.38
[The ultrasonic measurement of the endothelial function of the brachial artery in suspected coronary heart disease]. Dtsch Med Wochenschr (1999) 1.38
Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol (2006) 1.37
Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol (1994) 1.36
Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res (1994) 1.36
Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast (2005) 1.35
A review of parameters for the bioelectrical characterization of breast tissue. Ann N Y Acad Sci (1999) 1.34
Prevention of colonization and respiratory infections in long-term ventilated patients by local antimicrobial prophylaxis. Intensive Care Med (1987) 1.31
Cellular glycosylphosphatidylinositol-specific phospholipase D regulates urokinase receptor shedding and cell surface expression. J Cell Physiol (1999) 1.30
Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA). J Biol Chem (1991) 1.29
uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial. Adv Clin Chem (2008) 1.25
Measurement of the electron charge asymmetry in inclusive W production in pp collisions at sqrt[s]=7 TeV. Phys Rev Lett (2012) 1.23
Radiation therapy for intracranial germinoma: results of the German cooperative prospective trials MAKEI 83/86/89. J Clin Oncol (1999) 1.23
Expression of the RNA-binding protein IMP1 correlates with poor prognosis in ovarian carcinoma. Oncogene (2007) 1.23
Urokinase-type plasminogen activator antigen and early relapse in breast cancer. Lancet (1989) 1.22
Search for new physics in the multijet and missing transverse momentum final state in proton-proton collisions at √s = 7 TeV. Phys Rev Lett (2012) 1.19
Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients. J Clin Oncol (1998) 1.19
Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. J Natl Cancer Inst (1996) 1.19
Azimuthal anisotropy of charged particles at high transverse momenta in Pb-Pb collisions at sqrt[s(NN)] = 2.76 TeV. Phys Rev Lett (2012) 1.19
Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis. Cancer Res (2001) 1.19
Primary and secondary breast lymphoma: prevalence, clinical signs and radiological features. Br J Radiol (2012) 1.17
Nucleosomes in serum as a marker for cell death. Clin Chem Lab Med (2001) 1.17
First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis. J Clin Oncol (1999) 1.16
Methylated genes as new cancer biomarkers. Eur J Cancer (2009) 1.16
Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. Gynecol Oncol (2001) 1.16
Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer. Gynecol Oncol (2000) 1.16
Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling. J Cell Mol Med (2008) 1.15